Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2018–2021

COLOSTEO · Nutraceutical supplementation based on colostrum for prevention of osteoporosis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-01-01 → 2021-12-31
Финансиране от ЕС
828 000 €
Участници
5
Схема
MSCA-RISE

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Говеждото колизум се изследва като хранителна добавка за стимулиране на образуването на костна тъкан. Това е важно, защото съществуващите лекарства срещу остеопороза често предизвикват странични ефекти, а рискът от фрактури при хората нараства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Nutraceutical supplementation based on colostrum for prevention of osteoporosis

Osteoporosis constitutes a major public health concern; 1 in 3 women and 1 in 5 men are currently at risk for an osteoporotic fracture. In 2010, the economic burden of osteoporotic fractures in the European Union (EU) was approximately €37 billion. These costs are estimated to raise by 25% in the year 2025. Worldwide, by 2050, the incidence of osteoporotic fractures is expected to increase 310% in men and 240% in women compared to 1990. These estimates may indicate some ineffectiveness of currently available products aiming to prevent osteoporosis. In fact, the use of the marketed pharmacological agents for osteoporosis (e.g. bisphosphonates) has been decreasing in the EU. This is probably due to the reported side effects (as osteonecrosis of the jaw, atrial fibrillation and atypical femur fractures), and to the uncertainty of the positive long-term effects on bone formation. Calcium supplementation has also been reported to increase the risk of myocardial infarction. This means that there is a need for innovative products in order to reduce the current burden of osteoporosis. Bovine colostrum is a promising agent for osteoporosis prevention since it has natural components that seem to be directly involved in bone formation. As a nutracentical, colostrum confers an advantage over pharmacological agents since it can avoid the unpleasant side effects while inducing bone health benefits. The aim of COLOSTEO project is to produce new knowledge on the effects of bovine colostrum on bone formation and to create a nutracentical supplementation for osteoporosis prevention. To fulfil with this aim, COLOSTEO formed an intersectorial consortium involving academic and industrial partners. Academic partners have the scientific knowledge, facilities and experience to investigate the effects of colostrum on bone formation. Industrial partners have the expertise, experience and knowledge on manufacturing new products and marketing. Together, academia and industry will: a) Analyse bovine colostrum components and its consume safety; b) Investigate the effectiveness of bovine colostrum in preventing bone loss using an animal model (osteoporotic rat); c) Study the effects of the supplement on bone formation in human participants; d) Dissemination of the results; e) Create a business plan for product commercialisation.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. Colostrum is a promising agent against bone loss since it has natural constituents that are directly involved in bone metabolism. As a nutraceutical, colostrum confers an advantage over pharmacological drugs since it can avoid side effects. However, the possibility of its use as a nutraceutical agent for osteoporosis have only received attention within the scientific community. The knowledge produced on the effects of colostrum on bone metabolism has not yet been transferred to the market because academic institutions lack on expertise to create a new product. On the other hand, industry has knowledge on product development, but lack expertise on research skills. In accordance, what hinders the creation of an innovative product based on colostrum for prevention of osteoporosis is the absence of an intersectorial collaboration. As consequence, there is a clearly gap between research on the matter and its application. COLOSTEO aims to fill in this gap by creating an intersectorial collaboration to exchange knowledge and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This aim will be achieved by bridging two academic with two industrial institutions that through intersectorial secondments will exchange knowledge, ideas and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз